Neighborhood Disadvantage Tied to Shorter Breast Cancer-Specific Survival
By Elana Gotkine HealthDay Reporter
FRIDAY, April 19, 2024 -- Neighborhood disadvantage is associated with shorter breast cancer-specific survival, according to a study published online April 18 in JAMA Network Open.
Neha Goel, M.D., M.P.H., from the University of Miami Miller School of Medicine, and colleagues examined whether neighborhood disadvantage is associated with shorter breast cancer-specific survival in a national retrospective cohort study involving patients with breast cancer diagnosed from 2013 to 2018. Data were included for 350,824 patients with breast cancer.
Overall, 25.0 and 14.9 percent of patients lived in the most advantaged and most disadvantaged neighborhoods, respectively. A larger number of non-Hispanic White patients lived in advantaged neighborhoods (76.2 percent), while the highest proportion of non-Hispanic Black and Hispanic patients was seen in disadvantaged neighborhoods (30.9 and 19.5 percent, respectively). Compared with the most advantaged neighborhoods, the most disadvantaged neighborhoods had the highest risk for mortality in a breast cancer-specific survival analysis (hazard ratio, 1.43).
"To address these residual disparities associated with neighborhood disadvantage, future research must take a translational epidemiologic approach to focus on biological and nonbiological factors through which the built environment, above the beyond individual-level factors, may influence outcomes," the authors write. "This approach to research has the potential to advance precision medicine in oncology by bringing neighborhood disadvantage into consideration when risk-stratifying vulnerable populations and to develop cancer control interventions to overcome breast cancer disparities."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.